摘要
阿尔采末病(AD)是一种常见的神经退行性疾病,目前尚无有效的治疗药物。随着AD发病机制研究的深入,β淀粉样蛋白(amyloid beta-peptide,Aβ)被认为是AD发病重要因素之一。因此,很多药物设计选择以Aβ为靶标,但这类药物的临床研究却受到不同程度的挫折,tramiprosate和semagacestat的临床试验已经提前终止。本文对目前进入临床试验Ⅲ期以Aβ为靶标的药物进行综述,以期为研究者提供参考。
Alzheimer＇ s disease （AD） is a chronic and progressive neurodegenerative disorder. To date, there is still no effective drug for it. With more understanding about the etiology and pathogenesis of AD, amyloid beta-peptide （Aβ） is considered to be an important factor. Therefore, results of these clinical trials with many drugs targeting Aβ were disappointed. Clinical trials of two drugs, tramiprosate and semagacestat have been terminated. The paper reviewed these drugs targeting Aβ in phase Ⅲ clinical trials, in order to provide reference services to researchers.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2012年第12期723-727,共5页
Chinese Journal of New Drugs and Clinical Remedies
